EPCAM and colorectal cancer: Current enrichment methods vary markedly in their approaches of CTC isolation and characterisation: from size- and gradient-based to dielectrophoresis and use of surface-based antigens like the EpCAM CellSearchTM System (Menarini-Silicon Biosystems, Castel Maggiore (BO), Italy), is the only FDA-approved method that monitors CTC levels in patients with prostate, breast and colorectal cancers.